RESULTS FOR : 'Gene Editing'
Showing 1 to 9 of 9 results |    
Keyword Search
Show#
Show#
Results Category/Section
CRISPR Cas9: transforming gene editing in drug discovery labs

It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to the genome.

Latest developments in high content screening systems.

High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, HCS imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of assays involving complex cellular disease models.

With synthetic biology, drug discovery is going virtual.

Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him are developing a genetic programming language for cells and applying synthetic biology to biotechnology challenges.

Synthetic lethality and anti cancer drug discovery

Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out.

Precise genome editing: the key to a CRISPR drug discovery pipeline?

From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in 2003, advances in our understanding of DNA have raised hopes that its direct manipulation at the level of the genome could revolutionise the drug discovery process.

Advancing the promise of therapeutic genomic editing.

The development of genome editing technology is revolutionising the study of gene function and has the potential to usher in a new class of therapeutics for a broad range of diseases.

The CRISPR/Cas9 system: cutting a path for rapid generation of more translational animal models.

The recent high-profile translational failures in mouse models have highlighted the need for more relevant animal models. Advances in gene editing tools, including the CRISPR/Cas9 system, have enabled the modification of highly translational organisms such as rats and rabbits, and have also greatly reduced model development timelines.

Gene Editing: Re-writing genomes with targetable nucleases. Fall 13

We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites, introduction of designed sequence changes and production of larger alterations, as desired by the experimenter. They are being used to explore gene function and create disease models and they hold great promise for human gene therapy.

Editing the Human Genome: role in functional genomics and translational medicine. Summer 12

It is now readily accepted that we are in a post genomic era. With the steady flow of genomic information available to researchers worldwide, the focus turns to ways to analyse this information effectively and then utilise it in a practical manner.